International Journal of Pharmaceutical research and Applications
Volume 9, Issue 1, Jan.-Feb. 2024, pp:1117-1124 www.ijprajournal.com ISSN: 2456-4494

Pharmacovigilance: An overview

Gadekar Aniket Chandrakant, Gaikwad Nikita Prakash, Dighe Vishal B.
[1,2,3,] *Student, Pravara rural college of pharmacy loni,maharastra*

Date of Submission: 03-02-2024 Date of acceptance: 14-02-2024

ABSTRACT: Pharmacovigilance is a dynamic and critical component of healthcare systems worldwide, dedicated to monitoring and evaluating the safety of pharmaceutical products post-market. This abstract offers a comprehensive overview of pharmacovigilance, emphasizing its fundamental principles, objectives, and its pivotal role in safeguarding public health.

The abstract begins by defining pharmacovigilance as the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It outlines the primary goals of pharmacovigilance, which include identifying and assessing adverse drug reactions (ADRs), understanding the risks and benefits of medications, and preventing harm to patients.

The historical context of pharmacovigilance is briefly explored, highlighting its evolution from a reactive system to a proactive and systematic approach. The abstract then delves into the key components of pharmacovigilance, such as spontaneous reporting, observational studies, and signal detection, illustrating how these methodologies contribute to the continuous monitoring of drug safety.

The importance of global collaboration and regulatory frameworks in harmonizing pharmacovigilance efforts is discussed, emphasizing the need for standardized procedures and information sharing to address challenges associated with diverse healthcare systems. The abstract also touches upon the role of technology and data analytics in enhancing signal detection and risk assessment.

Furthermore, the abstract highlights the involvement of healthcare professionals, regulatory authorities, and pharmaceutical companies in fostering a culture of transparency and reporting to ensure a robust pharmacovigilance system. The conclusion underscores the ongoing significance of pharmacovigilance in building trust among stakeholders, ensuring patient safety, and contributing to the overall success of healthcare systems.

In summary, this abstract provides a concise yet comprehensive overview of pharmacovigilance, offering insights into its historical evolution, key methodologies, global collaboration, and the crucial role it plays in maintaining drug safety and public health.

KEYWORDS: (Pharmacovigilance ,clinical trials ,adverse drug reactions ,ICH GCP guidelines, WHO DD.

.

I. INTRODUCTION

The etymological roots for the word "pharmacovigilance" are: Pharmakon (Greek)5medicinal substance, and Vigilia (Latin) 5to keep watch (Fornasier et al., 2018).

PV is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other DRP (WHO, 2002).

PV is defined by the European Commission (EU) as the "Process and science of monitoring the safety of medicines and taking action to reduce the risks and increase the benefits of medicines" (European Commission, 2018).(1)

The World Health Organization has defined PV as the "science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems.(2)

Pharmacovigilance has grown significantly in recent years and its importance in the healthcare system has been recognized worldwide. However, there are considerable issues which need to be addressed to ensure the safety of medicines.

According to the World Health Organization (WHO), pharmacovigilance also known as the "drug safety" is the science and activity relating to the detection, assessment, and prevention of adverse effects. The aim and scope of pharmacovigilance is broad and includes multiple components such as

International Journal of Pharmaceutical research and Applications
Volume 9, Issue 1, Jan.-Feb. 2024, pp:1117-1124 www.ijprajournal.com ISSN: 2456-4494

medication errors, counterfeit and unauthorized medicines, lack of efficacy, drug interactions, and rational prescription of medicines (3)

History

The history of Pharmacovigilance started 169 years ago, on Jan 29, 1848, when a young girl (Hannah Greener) from the north of England died after receiving chloroform anaesthetic before the removal of an infected toenail. Sir James Simpson discovered that chloroform was a safer and more powerful anaesthetic and introduced it into clinical practice. The causes of Hannah's death were investigated to understand what happened to Hannah, but it was impossible to identify what killed her. Probably she died of a lethal arrhythmia or pulmonary aspiration.(4) In 1906, the US Federal Food and Drugs Act was passed; this act required drugs to be pure and free from contamination, but there was no requirement for them to be efficacious. Nonetheless, there were 107 deaths in the USA in 1937 from the use of diethylene glycol as a solvent for sulfanilamide.(5)The 1938 Federal Food, Drug, and Cosmetic Act (FDCA) is a set of United States (US) laws that authorize the Food and Drug Administration (FDA) to oversee and regulate the production, sale, and distribution of food, drugs, medical devices, and cosmetics. The FDCA intends to protect the general public from adulterated and misbranded products manufactured and sold in the US. Its introduction was largely influenced by a mass poisoning event in which elixir sulfanilamide, an untested antibiotic containing the toxin diethylene glycol, led to over 100 deaths across 15 states(6)In 1961, the Australian physician McBride published a letter in which he suggested a connection between congenital malformations in newly born infants and the hypnotic thalidomide, which was marketed under various names in many countries(7)Yellow card" (YC) was structured in the UK ON 1964, it is a specific form to systemize a spontaneous report of drug toxicity. In Europe the disaster of thalidomide promoted the development of a European legislation with the EC Directive 65/65 on 1965.

In 1968, the WHO Programme for International Drug Monitoring was introduced and ten members take part in this program (Australia, UK, USA, Germany, Canada, Ireland, Sweden, Denmark, New Zealand, and Netherlands). Italy participated in this program in 1975. In 1992, the European Society of Pharmacovigilance (ESOP) was funded, changed to the International Society of Pharmacovigilance (IsoP). The focus of this society were to upgrade Pharmacovigilance, and improve all characteristics of the safe and proper use of medicines. The European Medicines Agency (EMA) was established on 1995. In 2001, EudraVigilance was funded. It is the official European database for managing and analysing information on suspected adverse reactions to medicines which have been authorized for the market or being studied in European clinical trials. A foremost change in European Pharmacovigilance was witnessed with the new legislation (Directive 2010/84/EU),), in 2012. Moreover, the new legislation set-up considers facilitating the performance of PV, called the Good Pharmacovigilance

Practices (GVP). The GVP guideline is divided into two classes: modules covering major Pharmacovigilance processes and product- or population-specific considerations. This last class is available for vaccines and biological medicinal products. In this guideline there are also special chapters dedicated to special areas, namely pregnancy and breast-feeding (P III) and

geriatric population (PV). In November 2017, the new EudraVigilance format was launched; in particular, the marketing authorizations will have extended access to the EudraVigilance database to support the attainment of their Pharmacovigilance obligations. This last

category is out there for vaccines and biological medicative merchandise. During this guideline there are special chapters dedicated to special areas, specifically maternity and breast feeding (P III) and geriatric population (PV), (8) Pharmacovigilance in India was originated in 1986 with an official adverse drug reaction (ADR) monitoring system, under direction of the drug controller of India. India joined the World Health Organization (WHO) Programme based in Uppsala,

Sweden. This attempt was unsuccessful and hence, from 1 January 2005, the WHO sponsored and World Bank-funded National Pharmacovigilance Program for India was made functioning. It was to be superintended by the National Pharmacovigilance Advisory Committee based in the Central Drugs Standard Control Organization (CDSCO), New Delhi. Two zonal centres the South-West zonal centre (situated in the Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai) and the North-East zonal centre (situated in the Department of Pharmacology, AIIMS, New Delhi), were to collect and combine information from all over the country and send it to the Committee as well as to the Uppsala monitoring centre in Sweden. Three regional centres would

International Journal of Pharmaceutical research and Applications
Volume 9, Issue 1, Jan.-Feb. 2024, pp:1117-1124 www.ijprajournal.com ISSN: 2456-4494

report to the Mumbai centre and two to the New Delhi one. Every regional centre in turn would have some peripheral centres reporting to it. Presently there are 26 peripheral centres. The program has three extensive objectives: the short-term objective is to encourage a reporting culture, the intermediate objective is to involve a large number of healthcare professionals in the system in information dissemination and the long- term objective is for the program to be a benchmark for global drug monitoring(9). 16 In 2010 National Programme of Pharmacovigilance was renamed as Pharmacovigilance Programme of India (PvPI),(10)

i. **Adverse drug reaction**

The most commonly used definition of an ADR is a response to a drug that is 'noxious, unintended and occurs at doses normally used in man'. This definition arose from the World Health Organization (WHO) report on International Drug Monitoring in 1972, and remains largely unchanged(11)

Types of adverse drug reactions

Adverse drug reactions are type A (pharmacological) or type B (idiosyncratic).7 Type A reactions represent an augmentation of the pharmacological actions of a drug. They are dose-dependent and are therefore readily reversible on reducing the dose or withdrawing the drug. In contrast, type B adverse reactions are bizarre and cannot be predicted from the known pharmacology of the drug.(12)

1.Type A Effects

Expanded (augment) pharmacological effect: These are expected effects & it is dose-related; these effects are due to overstated pharmacological impacts..

2. Type B Effects

Unusual effects (idiosyncratic or Bizarre):. These effects (type B) are uncommon & unpredictable.

3.Type C Effects

These effects are chronic and refer to medication utilization, frequently for obscure reasons, expanding the recurrence of a "spontaneous" ailment. These effects (Type C) are both common & critical (like malignant) & may affect general well-being.

4.Type D Effects

These impacts are delay onset effects . example : Teretogenic Effect.

5.Type E Effects

The effect of treatment ends. (13)

Adverse effect

The term "adverse effect" Is preferable to other terms such as "toxic effect" or "side effect". A toxic effect is one that occurs as an exaggeration of the desired therapeutic effect, and which is not common at normal doses. For example, a headache due to a calcium antagonist is a toxic effect—it occurs by the same mechanism as the therapeutic effect (vasodilatation). A toxic effect is always dose-related(14)

Adverse event

Harm that occurs while a patient is taking a given drug, whether caused by it or not.

Side-effect

Any effect caused by a drug other than the intended therapeutic effect, whether beneficial, neutral or harmful. The term is sometimes used as a synonym for 'adverse drug reaction' or to describe 'minor' and predictable ADRs (e.g. constipation with opiates.(15)

Clinical trials

A clinical trial is a study that tests a new medical treatment or a new way to use an existing treatment to see if it will be a better way to prevent, screen for, or treat a disease. Any new drug must pass preclinical studies before it can be used in a clinical trial(16).

Phases of clinical trials

Preclinical study

Pre-clinical examinations incorporate creature studies and assessments of medication creation and immaculateness. Creature studies investigate: 1) the drug's safety in doses that are equivalent to approximate human exposures, 2) pharmacodynamics, or the mechanisms of action and the relationship between drug levels and clinical response, and 3) pharmacokinetics, or the potential for drug–drug interactions. This information should be submitted for IND endorsement assuming that the medication is to be additionally concentrated on in human subjects.(17)

Phase 0

Stage 0 preliminaries are first-in-quite a while directed before standard stage I portion heightening medication wellbeing and decency testing. Under the auspices of the U.S. Food and Drug Administration's exploratory investigational new drug (ExpIND) guidance, phase 0 trials can be carried out with lower doses of the study agent administered for a limited period of time (approximately V7 days). Stage 0 preliminaries, notwithstanding, by tending to viability (i.e., target impacts) and additionally pharmacokinetic (PK) properties early, could kill failing to meet expectations specialists, subsequently keeping away from inefficient consumptions on additional preclinical wellbeing testing and pointless scale-up drug creation for bigger trials.(18)

International Journal of Pharmaceutical research and Applications
Volume 9, Issue 1, Jan.-Feb. 2024, pp:1117-1124 www.ijprajournal.com ISSN: 2456-4494

Phase 1

The pharmacokinetic and pharmacodynamic parameters, acute adverse effects with increasing doses, and early evidence of efficacy are all evaluated in phase I trials. They regularly include a modest number (20-80) of sound workers, in spite of the fact that for certain populaces, like those with hepatic or renal hindrance. These examinations are in many cases directed in a long term climate to consider close checking of the patient.5 Stage Ia studies are quick to be led in people. These are typically one-dose escalation studies that may be randomized but uncontrolled. The point is to decide the most extreme okay portion and distinguish intense antagonistic occasions and portion restricting poison levels. In Phase Ib trials, healthy adults or patients with the disease or condition being studied are the subjects. In Phase Ib studies, the dosage range for multiple doses is determined by the maximum tolerable dose. The drug's pharmacologic properties and tolerability are still being investigated in these trials. Stage Ib preliminaries can likewise give primer adequacy assessments.(19)

Phase 2

The second phase of clinical testing can begin for an experimental treatment once it has been found to be effective in Phase I. The objective of Stage II is to additionally examine the security and viability of the trial treatment. These examinations normally include a bigger gathering of members than Stage I (generally 100 - 300 patients), every one of whom have the condition the review treatment plans to treat.

Phase II trials typically conclude:

Whether the treatment is protected to provide for people
Which portions of the treatment are protected to provide for people
What aftereffects are related with the treatment (and how to oversee them)
Whether the treatment is powerful
The security and viability of the new treatment contrasted with existing medicines
Members in Stage II clinical preliminaries are generally given the most noteworthy "safe" portion of the treatment distinguished in Stage I. They are then observed for aftereffects and indications of powerful treatment.
In some Stage II preliminaries, members are isolated into at least two gatherings. While some members of one group may receive the standard treatment for their condition, others may receive the treatment under investigation. Different groups may receive the same therapies at different doses from time to time. Researchers are able to compare and contrast the efficacy of new and existing treatments by examining the treatment outcomes of these various groups. It additionally encourages how they might interpret the exploratory treatment's portion subordinate results (i.e., the impact on diseases and aftereffects each portion might create(20)

Phase 3

In light of earlier examinations showing drug wellbeing and potential effi cacy, a stage III preliminary (likewise alluded to as a "helpful confi rmatory," "relative effi cacy," or "significant preliminary") might be sought after. This phase of medication evaluation is led in a bigger and frequently more different objective populace to exhibit or potentially confi rm effi cacy and to distinguish and gauge the occurrence of normal unfriendly responses. In any case, considering that stage III preliminaries are generally no bigger than 300 to 3000 subjects, they thus have the measurable ability to lay out an unfavorable occasion pace of something like 1 of every 100 people (in light of Hanley's "Rule of 3").24 This features the signifi cance of stage IV preliminaries in recognizing more uncommon unfriendly medication responses, and is one motivation behind why the FDA ordinarily requires more than one stage III preliminary to lay out drug wellbeing and effi cacy.(21)

Phase 4

Stage IV preliminaries, otherwise called postmarketing preliminaries, are directed to additionally describe a medication's viability (adequacy under genuine circumstances) and security for the supported indication.2-5 These preliminaries help to characterize ideal use and to find more about the drawn out gambles related with the medication. Stage IV preliminaries might be commanded by FDA to accumulate extra wellbeing and viability information. Since these preliminaries are directed after the medication has been showcased, they are not expose to IND guidelines. From the 548 new chemical entities approved between 1975 and 1999, 56 (10.2%) received black-box warnings or were removed from the market as a result of adverse events discovered in Phase IV trials.(22)

ICH GCP GUIDELINES

The principals of ICH GCP –

1. Clinical preliminary ought to be directed in understanding with the moral administrators that have their starting point in the Announcement of Helsinki, and that are reliable with GCP and the material administrative prerequisite.

International Journal of Pharmaceutical research and Applications
Volume 9, Issue 1, Jan.-Feb. 2024, pp:1117-1124 www.ijprajournal.com ISSN: 2456-4494

2. Before a preliminary is started, predictable dangers and inconveniences ought to be weighed against the anticipated benefit for the singular preliminary subject and society. A preliminary ought to be started and proceeded only if the expected advantages legitimize the dangers.
3. The privileges, security, and prosperity of the preliminary subjects are the main contemplations and should prevail over the interests of science and society.
4.The accessible nonclinical and clinical data on an investigational item ought to be sufficient to support the proposed clinical preliminary.
5.Clinical preliminaries ought to be logically solid, portrayed in an unmistakable, nitty gritty convention.
6.A preliminary ought to be led in consistence with theprotocol that has gotten earlier institutional review board (IRB) free morals board of trustees (IEC)approval/ideal assessment.
7.The clinical consideration given to and clinical choices madeon sake of, subjects ought to continuously be theresponsibility of a certified doctor, or whenappropriate, of a certified dental specialist.
8.Every individual engaged with leading a preliminary shouldbe qualified by instruction, preparation, and experience toperform their particular errands.
9.Before participating in a clinical trial, every subject should be given free and informed consent.
10.All data from clinical trials ought to be recorded, handled, and stored in a way that makes it possible to accurately report, interpret, and verify it.
11. The classification of records that could identifysubjects ought to be secured, regarding the privacyand secrecy rules as per theapplicable administrative prerequisite.
12.Good manufacturing practice (GMP) should be followed when manufacturing, handling, and storing investigational products. Use them in accordance with the procedure for approval.
13.Frameworks with strategies that guarantee the quality ofevery part of the preliminary ought to be embedded. (23)

Methods of monitoring adverse drug reactions

ADR monitoring for safety evaluation is a complex process. Some of the generally followed monitoring methods are as follows.

Case reports

The distribution of single case reports, or case series, of ADRs in clinical writing is a significant method for identifying new and serious responses; particularly Type B responses. With responses, their significance is decreasing; especially those of Type B. Their significance is on the downfall with the development of unconstrained revealing frameworks. E.g. : Hepatitis caused by halothane.(24)

Case cohort studies

These studies include retrospective case–control studies as well as prospective cohort studies; as such, it is the mix of both the examinations (Pearson et al.1994).(25)

Record linkage

The thought here is to unite different patient records like general practice records of sickness occasions and general records of remedies. In this manner it very well might be feasible to coordinate ailment occasions with drugs recommended. A particular illustration of the utilization of record linkage is the purported remedy occasion observing plan in which every one of the solutions gave by chosen parishioners for a specific medication are gotten from the remedy estimating authority. The prescribers are then asked to let those in charge of the plan know about any changes in the patients who are taking the drugs. This plan is more affordable and tedious than other reconnaissance methods(26)

Intensive Monitoring

In the current regulatory landscape for medicines, intensive monitoring (IM) is one method of post-marketing active surveillance based on event monitoring that has received interest. For a particular timeframe, IM includes essential information assortment and is effectively centered around social occasion longitudinal data, mostly security, starting from the main day of medication use.(27)

Spontaneous ADR reporting systems

Unconstrained ADR detailing frameworks are significant since they are a savvy strategy that can prompt the recognition of new or uncommon ADRs.25 Unconstrained reports are gathered in data sets through various channels (drug organizations, public and global pharmacovigilance habitats or administrative specialists). ADRs are collected and exchanged through these databases, which belong to various institutes like the FDA and EMA in the United States. Following investigation of the unconstrained reports, signs of unidentified or potential ADRs are generated.(28)

Drug dictionary and coding

WHO-DD.

Most of WHO-DD sections allude to remedy just prescriptions, however numerous over-thecounter or drug specialist apportioned items are additionally included. Immunizations, biotech and blood items, diagnostics, and difference media are additionally covered somewhat.

The WHO-DD also includes herbal medicines with a new, one-of-a-kind classification system that is

International Journal of Pharmaceutical research and Applications
Volume 9, Issue 1, Jan.-Feb. 2024, pp:1117-1124 www.ijprajournal.com ISSN: 2456-4494

based on the anatomical-therapeutic chemical (ATC) classification and links to internationally recognized botanical names and synonyms (assigned in collaboration with the Royal Botanical Gardens, Kew, UK). This is a significant turn of events, taking into account the expanded utilization of herbals and customary drugs from one side of the planet to the other, and hence the expanded requirement for security observing of these items.
Because of its progressive construction, the WHO-DD takes into account information collection on the accompanying degrees of accuracy:
ATC, denoting the main indication for which a medicinal product is used; the ATC is in itself a hierarchy, with five levels
•generic (ingredient or combination of ingredients) level
•active or inactive moiety level
•pharmaceutical product level (combination of ingredients, form, and strength)
•medicinal product name level
•medicinal product level (referring to the named product marketed and sold in a particular country, with a particular ingredient, form, and strength(29)

MedDRA

depends on the Clinical Word reference for Medication Administrative Issues (MEDDRA), which was made by the UK Prescriptions Control Organization (MCA).MedDRA covers judgments, side effects and signs, antagonistic medication responses and helpful signs, the names and subjective aftereffects of examinations, careful and operations, and clinical/social history. By and large, just terms applicable to drug administrative undertakings are incorporated. (30)

WHO-ART

has been generally utilized for a long time to produce signals inside drug organizations and administrative specialists and the WHO-Craftsmanship PT stays the backbone of the sign location framework used by the WHO's Uppsala Checking Centre.(31)

Recent developments

1.Completeness Score for Indian Individual Case Safety Reports
2.Establishing the Culture of Adverse Drug Reaction Reporting
3.Integration of Pharmacovigilance Programme of India and National Aids Control Organization
4.Collaboration With Adverse Events Following Immunization
5.Collaborations With Central Drugs Standard Control Organization
6.Education and Training on Pharmacovigilance at Regional Training Centers
7.Android Mobile Application for Adverse Drug Reaction Reporting
8.Utilization of Periodic Safety Update Reports Reporting
9.Availability of Medicine Side Effect Reporting Form for Consumers in Different Vernacular Languages(32)

Conclusions

Pharmacovigilance is a critical component of drug safety and public health. It plays a key role in identifying, monitoring, and evaluating the safety of pharmaceutical products throughout their lifecycle. The primary goal of pharmacovigilance is to detect and assess adverse drug reactions (ADRs), ensuring that any potential risks associated with the use of medications are identified and managed promptly.

In conclusion, pharmacovigilance contributes significantly to patient safety by promoting the rational and safe use of medicines. It involves the collection, analysis, and interpretation of data related to the safety of drugs, and it facilitates communication and collaboration among healthcare professionals, regulatory authorities, and pharmaceutical companies. The continuous monitoring of drugs post-marketing, along with the reporting and analysis of adverse events, helps in making informed decisions about the benefits and risks of medications.

As the pharmaceutical landscape evolves with the introduction of new therapies and advancements, pharmacovigilance must adapt and incorporate innovative technologies and methodologies to enhance its effectiveness. Additionally, global collaboration and harmonization of pharmacovigilance efforts are crucial to address emerging challenges and ensure a robust and standardized approach to drug safety worldwide.

In summary, pharmacovigilance is indispensable in safeguarding public health, fostering transparency, and maintaining the trust of healthcare professionals and patients in the pharmaceutical industry. Continuous improvement, adaptability, and global cooperation are essential elements for the ongoing success of pharmacovigilance in ensuring the safety of medications and optimizing healthcare outcomes.

REFERENCES

[1]. Al-Worafi Y. Patient safety in developing countries: Education, research, case studies. CRC Press; 2023 Oct 5.

[2]. Beninger P. Pharmacovigilance: an overview. Clinical therapeutics. 2018 Dec 1;40(12):1991-2004.
[3]. Najafi S. Importance of pharmacovigilance and the role of healthcare professionals. J Pharmacovigil. 2018 Jan;6(1):1-2.
[4]. Agrawal P, Kushwaha V, Siddiqui S, Khan NF, Tripathi M. HISTORY OF PHARMACOVIGILANCE AND DRUG SAFETY.
[5]. Geiling EMK, Cannon PR. Pathogenic effects of elixir of sulfanilamide (diethylene glycol) poisoning. JAMA 1938; iii: 919.
[6]. Wax PM. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med. 1995 Mar 15;122(6):456-61. [PubMed]
[7]. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 11: 1358
[8]. Giulia Fornasier, Sara Francescon, Roberto Leone & Paolo Baldo. A historical overview over pharmacovigilance. International Journal of clinical pharmacy-40,744-747(2018).
[9]. V Kalaiselvan, Sushma Srivastava, Abhishank Singh, S K Gupta.Pharmacovigilance in India: Present Scenario and Future Challenges.Drug saf.2019Mar;42(3):339-346.
[10]. Kumar A. Past, Present and Future of Pharmacovigilance in India.Review Article 2010Sep.
[11]. Patton K, Borshoff DC. Adverse drug reactions. Anaesthesia. 2018 Jan;73:76-84.
[12]. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. Bmj. 1998 Apr 25;316(7140):1295-8.
[13]. Khalid Abbood M, Alaa Aldeen Khalaf H, H Abudlqader E, Sagban Taghi H, Alaa Al-Temimi A. Scope of Pharmacovigilance: Comprehensive Review. Chemical Science International Journal. 2022 Dec 31;31(5):29-39.
[14]. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The lancet. 2000 Oct 7;356(9237):1255-9
[15]. Ferner RE. Adverse drug reactions. Medicine. 2016 Jul 1;44(7):416-21
[16]. Thorat SB, Banarjee SK, Gaikwad DD, Jadhav SL, Thorat RM. Clinical trial: a review. International Journal of pharmaceutical sciences Review and Research. 2010 Mar;1(2):101-6.
[17]. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgraduate medicine. 2011 Sep 1;123(5):194-204.
[18]. Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M. Designing phase 0 cancer clinical trials. Clinical cancer research. 2008 Jun 15;14(12):3675-82
[19]. Nguyen V, Sweet BV, Macek T. Defining the phases of clinical trials. American Journal of Health-System Pharmacy. 2006 Apr 15;63(8):710-1.
[20]. Meghan Hosely, Marketing Content Manager, Phases of Clinical Research: A Detailed Overview. June 27, 2023
[21]. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgraduate medicine. 2011 Sep 1;123(5):194-204.
[22]. Lasser KE, Allen PD, Woolhandler SJ et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287:2215-20
[23]. Tejas D Kamble,Monika B Khatmode,Anuksha S Dombe,Ganesh R Phadtare,Shyam S. Awate ,review on preclinical and clinical studies, volume 11,3 march 2023.
[24]. KUMAR DN, Prasanth Y, Narendra B, Upendra K, Rajesh K. A review on Adverse drug reactions monitoring andreporting. International Journal of Pharmacy Research & Technology (IJPRT). 2019;9(2):12-5.
[25]. Sahu RK, Yadav R, Prasad P, Roy A, Chandrakar S. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus. 2014 Dec;3(1):1-9.
[26]. Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. J Pharm Res Health Care. 2010 Jan 1;2:127-34.
[27]. Torre C, Cary M, Borges FC, Ferreira PS, Alarcão J, Leufkens HG, Costa J, Martins AP. Intensive Monitoring Studies for Assessing Medicines: A Systematic Review. Frontiers in Medicine. 2019 Jul 19;6:147.
[28]. Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Therapeutic advances in drug safety. 2020 Aug;11:2042098620938595.
[29]. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Information Journal. 2008 Sep;42(5):409-19.
[30]. 30.Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities

(MedDRA). Drug safety. 1999 Feb;20(2):109-17.

[31]. Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug safety. 2002 May;25:445-52.

[32]. Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian journal of pharmacology. 2016 Nov;48(6):624.